Antibody Drug Conjugates (ADCs) are an exciting and challenging new area of research and are becoming ever more popular across the industry with more than 50 ADCs reported in the clinic. The targeted nature of the molecules makes them extremely suitable for delivering toxic molecules to the target.
However the complexity of the molecules and lack of regulatory experience increases the complexity in discovery and development across all disciplines.
This symposium brings together experts from across the industry to share their knowledge and learning for an engaging and exciting joint meeting with JPAG and DMDG.
However the complexity of the molecules and lack of regulatory experience increases the complexity in discovery and development across all disciplines.
This symposium brings together experts from across the industry to share their knowledge and learning for an engaging and exciting joint meeting with JPAG and DMDG.
